Roche reported positive Phase III results on trials of its new multiple sclerosis (MS) drug today. Fenebrutinib appears effective at treating both relapsing multiple sclerosis and primary progressive ...

Roche Holding AG (ISIN CH0012032048) stock is back in the spotlight as new phase III data for the cancer drug candidate ...

Roche Holding (SWX:ROP) announced a collaboration with Treeline Biosciences to study combination immunotherapies for B-cell ...

Roche Holdings AG (OTC:RHHBY) on Thursday presented new data at the AD/PD 2025 International Conference on Alzheimer’s and Parkinson’s Diseases. Highlights included presentations from the ongoing ...

Investors might want to bet on Roche Holding AG (RHHBY), as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one ...

At the close on September 4, 2026, Roche Holding stock finished at CHF 357.00 on the Swiss Exchange, adding 0.14% while the ...

RBC Capital analyst Trung Huynh maintained a Buy rating on Roche Holding AG today and set a price target of CHF400.00. Huynh covers the Healthcare sector, focusing on stocks such as Bristol-Myers ...

Roche Holding AG's Q2 and 1H 2025 earnings will, initially, broadly please the market despite recent pipeline and commercial setbacks. The pharmaceuticals division delivered strong revenue growth, up ...

Roche Holdings AG (OTC:RHHBY) on Friday announced new 96-week data for fenebrutinib demonstrating that patients with relapsing multiple sclerosis (RMS) maintained no disability progression and low ...

The Roche Holdings Inc.-Bond has a maturity date of 11/13/2026 and offers a coupon of 4.3691%. The payment of the coupon will tak ...

Roche reported positive Phase III results on trials of its new multiple sclerosis (MS) drug today. Roche Holding (OTC: RHHBY) stock jumped 3.4% through 1:05 p.m. ET Monday after the pharmaceutical ...